Adjuvant Therapy: Enhancing Cancer Treatment
Following the completion of a surgical procedure aimed at removing the tumor and adjacent tissues, medical professionals may recommend adjuvant therapy to further optimize the patient’s treatment. This approach proves particularly valuable when there is a high likelihood of cancer recurrence, providing a means to reduce such risks. However, it is important to note that adjuvant therapy may not necessarily extend the patient’s lifespan. Adjuvant therapy can take the form of radiation or chemotherapy, with its primary objective being the eradication of any remaining rapidly dividing cancer cells in the surgical area.
Pd-1 Inhibitors: A Promising Treatment for Melanoma
Pd-1 inhibitors have emerged as a revolutionary approach to treating melanoma. Two notable medications in this category are Nivolumab (Opdivo) and Pembrolizumab (Keytruda). These drugs target the PD-1, a protein found in T cells, a type of immune system cell. By blocking PD-1 and its impact on these cells, these medications enhance the immune system’s ability to combat melanoma. Additionally, they can effectively reduce tumor size and potentially extend the patient’s lifespan. To administer these medications, they are typically delivered intravenously in a scheduled manner, usually every two to three weeks.